|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
25,750,000 |
Market
Cap: |
460.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.1 - $22.08 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 14.6 |
Insider 6 Months : 14.6 |
Insider 3/6 Months : 29.5 |
|
Guru Rank Number : 140 |
Guru Rank Value : 7.2 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Harrow Health engages in the development, production and sale of medications. Co. owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical businesses. Through its subsidiaries, Visionology, Inc., which provides an online eye health platform; Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
179,000 |
179,000 |
257,300 |
699,568 |
Total Buy Value |
$1,948,031 |
$1,948,031 |
$2,938,957 |
$7,583,356 |
Total People Bought |
2 |
2 |
3 |
3 |
Total Buy Transactions |
7 |
7 |
13 |
15 |
Total Shares Sold |
0 |
0 |
0 |
40,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$504,800 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Opaleye Management Inc. |
10% Owner |
|
2024-04-25 |
4 |
B |
$9.97 |
$199,400 |
I/I |
20,000 |
3,815,000 |
1.5 |
75% |
|
Opaleye Management Inc. |
10% Owner |
|
2024-04-24 |
4 |
B |
$10.15 |
$84,093 |
I/I |
8,285 |
3,795,000 |
1.5 |
70% |
|
Opaleye Management Inc. |
10% Owner |
|
2024-04-23 |
4 |
B |
$10.29 |
$120,547 |
I/I |
11,715 |
3,786,715 |
1.5 |
70% |
|
Opaleye Management Inc. |
10% Owner |
|
2024-04-19 |
4 |
B |
$10.56 |
$310,391 |
I/I |
29,400 |
3,775,000 |
1.5 |
67% |
|
Opaleye Management Inc. |
10% Owner |
|
2024-03-28 |
4 |
B |
$12.82 |
$641,000 |
I/I |
50,000 |
3,745,600 |
1.5 |
32% |
|
Baum Mark L |
CHIEF EXECUTIVE OFFICER |
|
2024-03-22 |
4 |
B |
$11.59 |
$104,310 |
D/D |
9,000 |
2,137,525 |
2.81 |
52% |
|
Opaleye Management Inc. |
10% Owner |
|
2024-03-20 |
4 |
B |
$9.65 |
$488,290 |
I/I |
50,600 |
3,695,600 |
1.5 |
66% |
|
Saharek John P. |
CEO of ImprimisRx |
|
2024-03-01 |
4 |
OE |
$8.75 |
$43,750 |
D/D |
5,000 |
254,803 |
|
- |
|
Baum Mark L |
CHIEF EXECUTIVE OFFICER |
|
2024-02-20 |
4 |
OE |
$10.67 |
$638,450 |
D/D |
59,836 |
2,128,525 |
|
- |
|
Baum Mark L |
CHIEF EXECUTIVE OFFICER |
|
2024-02-20 |
4 |
OE |
$10.67 |
$1,600,500 |
D/D |
150,000 |
2,188,361 |
|
- |
|
Boll Andrew |
CHIEF FINANCIAL OFFICER |
|
2024-02-20 |
4 |
OE |
$10.67 |
$197,182 |
D/D |
18,480 |
568,089 |
|
- |
|
Boll Andrew |
CHIEF FINANCIAL OFFICER |
|
2024-02-20 |
4 |
OE |
$10.67 |
$480,150 |
D/D |
45,000 |
586,569 |
|
- |
|
Saharek John P. |
CEO of ImprimisRx |
|
2024-02-20 |
4 |
OE |
$10.67 |
$134,613 |
D/D |
12,616 |
249,803 |
|
- |
|
Saharek John P. |
CEO of ImprimisRx |
|
2024-02-20 |
4 |
OE |
$10.67 |
$320,100 |
D/D |
30,000 |
262,419 |
|
- |
|
Boll Andrew |
CHIEF FINANCIAL OFFICER |
|
2024-02-07 |
4 |
OE |
$7.71 |
$57,054 |
D/D |
7,400 |
541,569 |
|
- |
|
Baum Mark L |
CHIEF EXECUTIVE OFFICER |
|
2024-02-07 |
4 |
OE |
$7.71 |
$118,734 |
D/D |
15,400 |
2,038,361 |
|
- |
|
Baum Mark L |
Chief Executive Officer |
|
2023-11-16 |
4 |
B |
$8.11 |
$60,825 |
D/D |
7,500 |
2,022,961 |
2.81 |
54% |
|
Opaleye Management Inc. |
10% Owner |
|
2023-11-15 |
4 |
B |
$8.03 |
$200,735 |
I/I |
25,000 |
3,645,000 |
1.5 |
57% |
|
Saharek John P. |
Chief Commercial Officer |
|
2023-11-10 |
4 |
D |
$12.83 |
$125,452 |
D/D |
(9,778) |
232,419 |
|
- |
|
Saharek John P. |
Chief Commercial Officer |
|
2023-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
242,197 |
|
- |
|
Opaleye Management Inc. |
10% Owner |
|
2023-09-20 |
4 |
B |
$14.49 |
$86,710 |
I/I |
5,983 |
3,620,000 |
1.5 |
-32% |
|
Opaleye Management Inc. |
10% Owner |
|
2023-09-19 |
4 |
B |
$14.65 |
$205,366 |
I/I |
14,017 |
3,614,017 |
1.5 |
-32% |
|
Baum Mark L |
Chief Executive Officer |
|
2023-08-14 |
4 |
B |
$17.05 |
$98,890 |
D/D |
5,800 |
2,015,461 |
2.81 |
-42% |
|
Makary Martin A. |
Director |
|
2023-08-14 |
4 |
B |
$16.92 |
$338,400 |
D/D |
20,000 |
45,000 |
2.39 |
-42% |
|
Boll Andrew |
Chief Financial Officer |
|
2023-07-18 |
4 |
D |
$18.23 |
$2,485,661 |
D/D |
(136,350) |
534,169 |
|
- |
|
181 Records found
|
|
Page 1 of 8 |
|
|